Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 02, 2015 11:54 PM ET

Pharmaceuticals

Company Overview of Takeda Pharmaceuticals International GmbH

Company Overview

Takeda Pharmaceuticals International GmbH manufactures and markets patented products, branded generics, and over-the-counter products that treat patients in various therapeutic areas in Asia, North America, Europe, Latin America, the Russian Federation-CIS, China, and internationally. It offers products in the therapeutic areas of cardiovascular and metabolic, oncology, central nervous system, respiratory and immunology, general medicine (gastrointestinal and genitourinary), and vaccines. The company also provides clinical development, contract manufacturing, product launch, packaging, and process optimization and formulation services. Takeda Pharmaceuticals International GmbH was formerly k...

Thurgauerstrasse 130

Glattpark-Opfikon,  8152

Switzerland

Founded in 1874

Phone:

41 44 555 10 00

Fax:

41 44 555 10 01

Key Executives for Takeda Pharmaceuticals International GmbH

Chief Executive Officer
Age: 69
Corporate Officer and President of Europe & Canada Business Unit
Head of Commercial Operations - Emerging Markets
Executive Vice President of Human Resources and IS/IT
Age: 57
Director of External Communications
Compensation as of Fiscal Year 2015.

Takeda Pharmaceuticals International GmbH Key Developments

Takeda Pharmaceuticals International GmbH Announces Vedolizumab for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis and Crohn's Disease

Takeda Pharmaceuticals International GmbH announced that data highlighting the efficacy and safety of vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease (CD) were presented at the 2015 Digestive Disease Week Annual Meeting in Washington, D.C. Twelve Takeda-sponsored presentations, including one oral presentation, were featured during the meeting May 16-19, 2015. The presentations included data from the Phase 3 pivotal studies GEMINI 1 (UC) and GEMINI 2 (CD), as well as interim data from the ongoing, open-label extension study GEMINI LTS. The GEMINI 1 and 2 studies are two randomized double-blind, placebo-controlled studies examining the efficacy and safety of vedolizumab for induction and maintenance in adult patients with moderately to severely active UC and CD, respectively. GEMINI LTS is a Phase 3, ongoing, open-label extension study examining the long-term safety and efficacy of vedolizumab for the treatment of adults with moderately to severely active UC and CD. Findings from an analysis of cost per-clinical-outcome for the treatment of moderately to severely active UC with biologic therapy were highlighted during an oral presentation on Saturday, May 16, 2015, as part of a larger session titled 'Bending the Cost Curve in Gastroenterology'.

Takeda Pharmaceuticals International GmbH Presents at 8th Annual EUROPEAN LIFE SCIENCE CEO FORUM & EXHIBITION, Mar-04-2015 08:30 AM

Takeda Pharmaceuticals International GmbH Presents at 8th Annual EUROPEAN LIFE SCIENCE CEO FORUM & EXHIBITION, Mar-04-2015 08:30 AM. Venue: Hilton, Zurich Airport Hotel, Hohenbuehlstrasse 10, Opfikon-Glattbrugg 8152 Zurich, Zurich, Switzerland. Speakers: Jane Atkins, Global Licensing & BD, Director, Search & Evaluation.

Takeda Pharmaceutical International GmbH Announces Results of the REACT Study Demonstrating Daxas

Takeda Pharmaceutical International GmbH announced results of the REACT study demonstrating Daxas(roflumilast) significantly reduced exacerbations and hospitalizations in patients with severe chronic obstructive pulmonary disease (COPD), who are at risk of frequent and severe exacerbations despite already receiving inhalation therapy with ICS/LABA combinations or triple (LAMA/ICS/LABA) therapy. The study showed that roflumilast significantly reduced the rate of severe exacerbations by 24.3% (p=0.0175) and those requiring hospitalization by 23.9% (p=0.0209), reducing the clinical and economic burden of this disease. In patients receiving triple therapy, roflumilast significantly reduced the rate of severe exacerbations by 23.3%(p=0.0406), indicating how patients with severe COPD may benefit most from the addition of roflumilast to their therapeutic regimen. These results have been published online in The Lancet. To prevent exacerbations and possible hospitalization, patients with severe COPD are treated with inhaled long-acting muscarinic antagonist alone and/or a fixed combination of inhaled corticosteroids/long-acting ß2-agonists (ICS/LABA). Despite access to these inhaled medications, a significant number of COPD patients still suffer from frequent exacerbations, impacting their overall health and accelerating lung function decline, leading to substantial morbidity and mortality. Already approved as an add-on therapy to long acting bronchodilators for severe COPD, the double-blind REACT study investigated roflumilast as an effective add-on therapy for the reduction of exacerbations, improved lung function and major adverse cardiac events in patients not adequately controlled with ICS/LABA combinations or triple LAMA/ICS/LABA therapy in maximal approved dosage. In the overall study population there was a reduction in the rate of moderate-to-severe exacerbations by 13.2%(p=0.0529) using a Poisson regression analysis and by 14.2%(p=0.0424) in a predefined sensitivity analysis using negative binomial regression, when compared with the placebo. Roflumilast showed a statistically significant improvement in lung function, with a 56 mL (p<0.0001) increase in post-bronchodilator FEV1 and 92 mL increase in FVC, compared to placebo.

Similar Private Companies By Industry

Company Name Region
Cilag AG International Zug Europe
Acino Pharma AG Europe
Alpex Pharma SA Europe
Rhenochem AG Europe
Metriopharm AG Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Takeda Pharmaceuticals International GmbH, please visit www.tpi.takeda.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.